Biological Effects of Fibrinogen-Fibrin Degradation Products^[*]

• References

• 1 Alkjaersig N, Fletcher A. P, and Sherry S. 1962; Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. II. The significance, mechanism and consequences of defective fibrin polymerization. Journal of Clinical Investigation 41: 917.
• 2 Bang N. U, Fletcher A. P, Alkjaersig N, and Sherry S. 1962; Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. III. Demonstration of abnormal clot structure by electron microscopy. Journal of Clinical Investigation 41: 935.
• 3 Budzynski A. Z, Marder V. J, and Shainoff J. R. 1974; Structure of Plasmic Degradation Products of human fibrinogen. Fibrinopeptide and polypeptide chain analysis. Journal of Biological Chemistry 249: 2294.
• 4 Budzynski A. Z, Stahl M, Kopec M, Latallo Z. S, Wegrzynowicz Z, and Kowalski E. 1967; High molecular weight products of the late stage of fibrinogen proteolysis by plasmin and their structural relation to the fibrinogen molecule. Biochimica Biophysica Acta 147: 313.
• 5 Buluk K, and Malofiejew M. 1969; The pharmacological properties of fibrinogen degradation products. British Journal of Pharmacology 35: 79.
• 6 Catanzaro A, and Edgington T. S. 1974; The in vivo behavior of the terminal derivatives of fibrinogen and fibrin cleaved by plasmin. Journal of Laboratory and Clinical Medicine 83: 458.
• 7 Catanzaro A, Hathaway G, Strathern J, and Edgington T. 1972; Structure and in vivo behavior of human fibrinogen fragment-D¹ . Proceedings of the Society for Experimental Biology and Medicine 139: 1401.
• 8 Culasso D. E, Donat M. B, de Gaetano G, Vermylen J, and Verstraete M. 1974; Inhibition of human platelet aggregation by plasmin digests of human and bovine fibrinogen preparations : Role of contaminating Factor VITI related material. Blood 44: 169.
• 9 Fletcher A. P, Alkjaersig N, Fisher S, and Sherry S. 1966; The proteolysis of fibrinogen by plasmin : the identification of thrombin-clottable fibrinogen derivatives which polymerize abnormally. Journal of Laboratory and Clinical Medicine 68: 780.
• 10 Hayne O. A, and Sherman L. A. 1973; In vivo behavior of fibrinogen fragment D in experimental renal, hepatic and reticuloendothelial dysfunction. American Journal of Pathology 71: 219.
• 11 Jerushalmy Z, and Zucker M. B. 1966; Some effects of fibrinogen degradation products (FDP) on blood platelets. Thrombosis et Diathesis Haemorrhagica 15: 413.
• 12 Kopec M, Teisseyre E, Dudek-Wojciechowska G, Kloczewiak M, Pankiewick A, and Latallo Z. S. 1973; Studies on the “Double D” fragment from stabilized bovine fibrin. Thrombosis Research 2: 283.
• 13 Kowalska-Loth B, Gardlund B, Egberg N, and Blombäck B. 1973; Plasmic degradation products of human fibrinogen. II. Chemical and immunological relation between Fragment E and N-DSK. Thrombosis Research 2: 423.
• 14 Kowalski E, Budzynski A. Z, Kopec M, Latallo Z. S, Lipinski B, and Wegrzynowicz Z. 1964; Studies on the molecular patholgy and pathogenesis of bleeding in severe fibrinolytic states in dogs. Thrombosis et Diathesis Haemorrhagica 12: 69.
• 15 Kowalski E, Kopec M, and Wegrzynowicz Z. 1963; Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesiveness and viscous metamorphosis. Thrombosis et Diathesis Haemorrhagica 10: 406.
• 16 Larrieu M. J. 1970; Action of fibrinogen degradation products and fibrin monomer soluble complexes on platelet aggregation. Scandinavian Journal of Haematology Suppl. N° 13: 273.
• 17 Larrieu M. J, Inceman S, and Marder V. 1967; Action des produits de degradation du fibrinogène sur les fonctions plaquettaires. Nouvelle Revue Française d’Hématologie 7: 691.
• 18 Larrieu M. J, Rigollot C, and Marder V. J. 1972; Comparative effects on fibrinogen degradation Fragments D and E on coagulation. British Journal of Haematology 22: 719.
• 19 Latallo Z. S, Budzynski A, Lipinski B, and Kowalski E. 1964; Inhibition of thrombin and of fibrin polymerization, two activities derived from plasmin-digested fibrinogen. Nature 203: 1184.
• 20 Latallo Z. S, Fletcher A. P, Alkjaersig N, and Sherry S. 1962; Inhibition of fibrin polymerization by fibrinogen proteolysis products. American Journal of Physiology 202: 681.
• 21 Marder V. J, and Budzynski A. Z. 1971; Classification of fibrinogen derivatives. In Thrombosis: Risk factors and Diagnosic approaches. Thrombosis et Diathesis Haemorrhagica Suppl.51: 267.
• 22 Marder V. J, and Budzynski A. Z. 1974; Degradation products of Fibrinogen and Crosslinked Fibrin. Projected clinical applications. Thrombosis and Diathesis Haemor-rhogica 32: 49.
• 23 Marder V. J, Budzynski A. Z, Solum N. D, Sevy R, and Rigollot C. 1973. A quantitative study of physiologic effects of peptide derived from human fibrinogen by plasmin digestion in “Protides of the Biological Fluids”. 20th Colloquium Peeters H. ed. Pergamon Press; Oxford and New York: 295.
• 24 Marder V. J, and Shulman N. R. 1969; High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. Journal of Biological Chemistry 244: 2120.
• 25 Marder V. J, Shulman N. R, and Carrol W. R. 1967; The importance of intermediate degradation products of fibrinogen in fibrinolytic haemorrhage. Transactions of the Association of American Physicians 80: 156.
• 26 Mosesson M. W, Finlayson J. S, and Galanakis D. K. 1973; The essential covalent structure of human fibrinogen evinced by analysis of derivatives formed during plasmic hydrolysis. Journal of Biological Chemistry 247: 5223.
• 27 Niewiarowski S, GuREWiCH V, Senyi A. F, and Mustard J. R. 1971; The effect of fibrinolysis on platelet function. Thrombolytic therapy (Ed. by E. F. Mammem, G. F. Anderson et M. I. Barnhardt). Thrombosis et Diathesis Haemorrhagica Suppl.47: 99.
• 28 Niewiarowski S, and Kowalski E. 1958; Un nouvel anticoagulant dérivé du fibrinogène. Revue d’Hématologie 13: 320.
• 29 Otis P. T, and Rapaport S. I. 1973; Failure of fibrinogen degradation products to increase plasma fibrinogen in rabbits. Proceedings of the Society for Experimental Biology and Medicine 144: 124.
• 30 Pizzo S. V, Taylor Jr. L. M, Schwartz M. L, Hill R. L, and McKee P. A. 1973; Subunit structure of fragment D from fibrinogen and cross linked fibrin. Journal of Biological Chemistry 248: 4584.
• 31 Solum N. O, Rigollot C, Budzynski A. Z, and Marder V. J. 1973; A quantitative evaluation of the inhibition of platelet aggregation by low molecular weight degradation products of fibrinogen. British Journal of Haematology 24: 419.
• 32 Stachurska J, Latallo Z, and Kopec M. 1970; Inhibiton of platelet aggregation by dialysable fibrinogen degradation products (FDP). Thrombosis et Diathesis Haemorrhagica 23: 91.
• 33 Triantaphyllopoulos E, and Triantaphyllopoulos D. C. 1965; Thermostable anticoagulant from the anticoagulant fraction of incubated fibrinogen. British Journal of Haematology 11: 331.
• 34 Triantaphyllopoulos D. C. 1958; Anticoagulant effect of incubated fibrinogen. Canadian Journal of Biochemistry and Physiology 36: 249.